However, our strategy of combining patients from all three cohorts and subsequently randomizing into training and validation cohorts, overcomes these caveats as it ensured that the training and validation sets would include patients representing a broad spectrum of prostate status, from benign with low PSA to very high risk PCa. This evidence concerns the gene KLK3 and posterior cortical atrophy.